Literature DB >> 11115712

Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults.

F P Kroon1, J T van Dissel, E Ravensbergen, P H Nibbering, R van Furth.   

Abstract

The antibody production by HIV-infected adults after two vaccinations with conjugated pneumococcal vaccine (CPV) and consecutive vaccination with polysaccharide pneumococcal vaccine (PPV) was studied. Thirty days after the second CPV, the geometric mean antibody concentrations (GMC) against pneumococcal polysaccharide serotypes (PPS) 6B, 14 and 19F were significantly lower in the group HIV-infected individuals with <200x10(6)/l CD4(+) T lymphocytes (group 1) than in the group with >/=200x10(6)/l CD4(+) T lymphocytes (group 2) and healthy controls. Thirty days after PPV vaccination the GMC against PPS 6B, 14, 19F and 23F in group 1, and against 6B and 19F in group 2, were significantly lower compared with healthy controls. Both in HIV-infected and in healthy individuals who received CPV and PPV the postvaccination GMC against PPS 14, 19F and 23F were higher compared with historical controls who were not previously immunized with CPV but only received PPV. We conclude that the antibody response to CPV is impaired in HIV-infected individuals. Higher antibody concentrations were achieved in HIV-infected and healthy individuals after sequential vaccination with CPV and PPV compared with PPV vaccination alone.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11115712     DOI: 10.1016/s0264-410x(00)00232-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

Review 1.  Economic aspects of pneumococcal pneumonia: a review of the literature.

Authors:  Diana De Graeve; Philippe Beutels
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 2.  Vaccination in HIV-infected adults.

Authors:  Nancy F Crum-Cianflone; Mark R Wallace
Journal:  AIDS Patient Care STDS       Date:  2014-07-16       Impact factor: 5.078

Review 3.  Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis.

Authors:  Solen Kernéis; Odile Launay; Clément Turbelin; Frédéric Batteux; Thomas Hanslik; Pierre-Yves Boëlle
Journal:  Clin Infect Dis       Date:  2014-01-10       Impact factor: 9.079

4.  Quantitative and Functional Antibody Responses to the 13-Valent Conjugate and/or 23-Valent Purified Polysaccharide Vaccine in Aging HIV-Infected Adults.

Authors:  Jennifer A Ohtola; Jessica L Saul-McBeth; Anita S Iyer; David J Leggat; Sadik A Khuder; Noor M Khaskhely; Ma Julie Westerink
Journal:  J AIDS Clin Res       Date:  2016-03-14

5.  Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy.

Authors:  Ching-Lan Lu; Chien-Ching Hung; Yu-Chung Chuang; Wen-Chun Liu; Chin-Ting Su; Yi-Ching Su; Shu-Fang Chang; Sui-Yuan Chang; Shan-Chwen Chang
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

6.  Association of time since pneumococcal polysaccharide vaccine receipt and CD4 count with antibody response to the 13-valent pneumococcal conjugate vaccine in HIV-infected adults.

Authors:  Alexandria E-B Rossheim; Anna Marie P Young; Julia Siik; Tina D Cunningham; Stephanie B Troy
Journal:  Hum Vaccin Immunother       Date:  2016-05-12       Impact factor: 3.452

7.  A human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infection.

Authors:  Kevin Fabrizio; Abraham Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2007-02-14

Review 8.  Pneumococcal vaccination among HIV-infected adult patients in the era of combination antiretroviral therapy.

Authors:  Kuan-Yeh Lee; Mao-Song Tsai; Kuang-Che Kuo; Jen-Chih Tsai; Hsin-Yun Sun; Aristine C Cheng; Sui-Yuan Chang; Chen-Hsiang Lee; Chien-Ching Hung
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

9.  Cross-sectional study of nasopharyngeal carriage of Streptococcus pneumoniae in human immunodeficiency virus-infected adults in the conjugate vaccine era.

Authors:  Chinwendu Onwubiko; Edwin Swiatlo; Larry S McDaniel
Journal:  J Clin Microbiol       Date:  2008-09-24       Impact factor: 5.948

Review 10.  Should the new pneumococcal vaccine be used in high-risk children?

Authors:  A Finn; R Booy; R Moxon; M Sharland; P Heath
Journal:  Arch Dis Child       Date:  2002-07       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.